ReviewCurrent opinion in HIV and AIDS2017
Combination antiretroviral therapy and cancer risk.
Review in Current opinion in HIV and AIDS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Cancer Prevention Pathways in People Living with HIV: Assessment of Prevalence and Related Factors Among Individuals Attending HIV Division of Ferrara Hospital.Journal of personalized medicine · 2025Article
- Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China.Scientific reports · 2024Article
- Cancer in People with HIV.Infectious disease clinics of North America · 2024Review
- "I Thought Cancer was a Tobacco Issue": Perspectives of Veterans with and without HIV on Cancer and Other Health Risks Associated with Alcohol and Tobacco/Nicotine Use.AIDS and behavior · 2024Article
- Needs of Training in Infection-Associated Cancer in Mali Besoins en Formation sur les Cancers Associés aux Infections au Mali.Revue malienne d'infectiologie et de microbiologie · 2024Article
- Estimates of the global burden of non-Hodgkin lymphoma attributable to HIV: a population attributable modeling study.EClinicalMedicine · 2024Article
- Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.Pathogens (Basel, Switzerland) · 2023Review
- Article
- Trends in the Incidence of Kaposi's Sarcoma and Non-Hodgkin Lymphoma in Northern Thailand during the Time Period of Universal Access to Antiretroviral Treatment, 1998-2017.Asian Pacific journal of cancer prevention : APJCP · 2023Observational
- The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China.Frontiers in oncology · 2023Article
- SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.Journal of virology · 2022Article
- HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers.Biomedicines · 2022Review
- How Much Does HIV Positivity Affect the Presence of Oral HPV? A Molecular Epidemiology Survey.International journal of environmental research and public health · 2021Article
- Cancer incidence and risk factors in dialysis patients with human immunodeficiency virus: a cohort study.Clinical kidney journal · 2021Article
- Awareness of Cancer Risk Factors and Its Signs and Symptoms in Northern Tanzania: a Cross-Sectional Survey in the General Population and in People Living with HIV.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.International journal of cancer · 2020Article
- Malignancy and all-cause mortality; incidence in adolescents and young adults living with perinatally acquired HIV.Journal of virus eradication · 2020Article
- Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer.Frontiers in oncology · 2020Article
- Impact of Helminth Infections on Female Reproductive Health and Associated Diseases.Frontiers in immunology · 2020Review
- HIV and the growing health burden from noncommunicable diseases in Botswana: modelling study.Journal of global health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk. RECENT
findingsHIV+ persons are at increased risk of cancer. As this risk is higher for malignancies driven by viral and bacterial coinfections, classifying malignancies into infection-related and infection-unrelated has been an emerging trend. Cohorts have detected major reductions in the incidence of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) following cART initiation among immunosuppressed HIV+ persons. However, recent randomized data indicate that cART reduces risk of Kaposi sarcoma and NHL also during early HIV infection before overt immunosuppression occurs. Long-term effects of cART exposure on cancer risk are not well defined; according to basic and epidemiological research, there might be specific associations of each cART class with distinct patterns of cancer risk. SUMMARY: The relationship between cART exposure and cancer risk is complex and nuanced. It is an intriguing fact that, whether initiated during severe immunosuppression or not, cART reduces risk of Kaposi sarcoma and NHL. Further research should identify mediators of the benefit of immediate cART initiation in reducing cancer risk, understand the relationship between long-term cART exposure and cancer incidence and assess whether adjuvant anti-inflammatory therapies can reduce cancer risk during treated HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.